论文部分内容阅读
目的 观察并了解利福昔明治疗急性肠炎的有效性和安全性。方法 采用随机对照方法 ,共治疗 5 1例急性肠炎 ,利福昔明治疗 2 5例 ,环丙沙星 2 6例 ,用药时间方法相同。观察临床症状 ,大便性状、次数 ,血、尿、粪常规及肝肾功能。结果 利福昔明组 (治疗组 )与环丙沙星组 (对照组 )相比 ,显效率分别为 92 0 0 %和 80 77% ,总有效率分别为 92 0 0 %和 96 15 % ,止泻时间为 (2 8 6 7± 15 92 )h和 (36 12± 2 0 70 )h ,均未见明显毒副作用。以上各项指标及两组在治疗过程中大便次数变化、粪常规复常率经统计学处理差异均无显著性 (P >0 0 5 )。结论 利福昔明可用于治疗急性肠炎 ,疗效与环丙沙星相仿 ,但口服不吸收 ,耐受性好。
Objective To observe and understand the efficacy and safety of rifaximin in the treatment of acute enteritis. Methods A total of 51 cases of acute enteritis were treated with randomized controlled trial. Twenty-five cases were treated with rifaximin and 26 cases were treated with ciprofloxacin. The treatment time was the same. Observation of clinical symptoms, stool traits, frequency, blood, urine, fecal routine and liver and kidney function. Results Compared with ciprofloxacin group (control group), the effective rates of rifaximin group (treatment group) were 92 0 0% and 80 77%, respectively. The total effective rates were 92 0 0% and 96 15% respectively. The antidiarrheal time was (2 8 6 7 ± 15 92) h and (36 12 ± 2 0 70) h, respectively, with no obvious side effects. The above indicators and changes in the number of stool in the two groups during treatment, normal fecal routine statistical differences were not statistically significant (P> 0.05). Conclusions Rifaximin can be used in the treatment of acute enteritis. The efficacy is similar to that of ciprofloxacin, but it is not orally absorbed and well tolerated.